Proton therapy for head and neck cancer: Rationale, potential indications, practical considerations, and current clinical evidence

Authors

  • Nancy P. Mendenhall University of Florida Proton Therapy Institute, Jacksonville, Florida, USA
  • Robert S. Malyapa University of Florida Proton Therapy Institute, Jacksonville, Florida, USA
  • Zhong Su University of Florida Proton Therapy Institute, Jacksonville, Florida, USA
  • Daniel Yeung University of Florida Proton Therapy Institute, Jacksonville, Florida, USA
  • William M. Mendenhall University of Florida Proton Therapy Institute, Jacksonville, Florida, USA
  • Zuofeng Li University of Florida Proton Therapy Institute, Jacksonville, Florida, USA

DOI:

https://doi.org/10.3109/0284186X.2011.590147

Abstract

There is a strong rationale for potential benefits from proton therapy (PT) for selected cancers of the head and neck because of the opportunity to improve the therapeutic ratio by improving radiation dose distributions and because of the significant differences in radiation dose distribution achievable with x-ray-based radiation therapy (RT) and PT. Comparisons of dose distributions between x-ray-based and PT plans in selected cases show specific benefits in dose distribution likely to translate into improved clinical outcomes. However, the use of PT in head and neck cancers requires special considerations in the simulation and treatment planning process, and currently available PT technology may not permit realization of the maximum potential benefits of PT. To date, few clinical data are available, but early clinical experiences in sinonasal tumors in particular suggest significant improvements in both disease control and radiation-related toxicity.

Downloads

Download data is not yet available.

Downloads

Published

2011-08-01

How to Cite

Mendenhall, N. P., Malyapa, R. S., Su, Z., Yeung, D., Mendenhall, W. M., & Li, Z. (2011). Proton therapy for head and neck cancer: Rationale, potential indications, practical considerations, and current clinical evidence. Acta Oncologica, 50(6), 763–771. https://doi.org/10.3109/0284186X.2011.590147